医学
熊去氧胆酸
胃肠病学
内科学
失调
益生菌
肠道菌群
病因学
原发性胆汁性肝硬化
免疫系统
肝病学
医学微生物学
原发性硬化性胆管炎
胆道
药物治疗
菌群(微生物学)
抗生素
肝硬化
利福昔明
作者
Xuan Rong Tang,Xin You
出处
期刊:Gut Pathogens
[BioMed Central]
日期:2025-11-10
卷期号:17 (1): 86-86
被引量:3
标识
DOI:10.1186/s13099-025-00753-w
摘要
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease. Current therapeutic options are limited, with some patients responding poorly to first-line treatment with ursodeoxycholic acid. However, second-line drugs are difficult to develop. There are no drugs available to treat liver dysfunction. Currently, the etiology of PBC is unknown, and the intestinal flora affects the liver through the gut‒liver axis. The hypothesis of intestinal dysbiosis has gradually been accepted and involves mechanisms such as leaky gut, abnormal bile acids metabolism, and dysregulated immune tolerance. We found that gut microbiota-targeted therapy, including antibiotics, dietary regulation, probiotic supplementation, and fecal microbiota transplantation, can effectively improve liver function, remodel the intestinal microbiota, and alleviate symptom. However, this therapy has limitations, such as large individual differences and unknown long-term efficacy and safety. Large-scale and long-term clinical studies are expected to promote the broad application of gut microbiota-targeted therapy in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI